LIVE
TechiPhone Duo buyers line up days early despite high chance of heartbreakMarketsVirginia state Sen. L. Louise Lucas, a Trump critic, charged in marijuana racketeering caseMarketsWedbush assumes coverage of five housing-related stocks after recent underperformanceLocalCompass sues former ERA president Alex Vidal over move to REMAXTechCoolfly’s solar-powered Aura Smart Bird Feeder is nearly 50 percent offTechApple Will Label Apps 'Made for iPhone Duo' in App StoreMarketsBrent crude rises to five-month high after more deadly attacks in Saudi ArabiaScienceThere should be black holes in our neighborhood. Can we find them?MarketsCBRE signals path to 15% core EPS growth in 2027 as it targets nearly $7B in infrastructure services revenueLocalCalifornia's Proposition 40: What voters need to know about billionaire wealth tax battleMarketsFireblocks disputes report of $2.5B Visa acquisition talksMarketsAmerican Express Q3 earnings watchlist: revenue, card spending, costsMarketsOmega Healthcare Investors raised to Buy-equivalent at Citizens after stock cools from 52-week highLocalIlhan Omar home raid, Haines attack: Inside rise in violence on officialsMarketsNvidia continues impressive path at GTC Berlin, BNP Paribas saysMarketsHBAR Risks a Retreat Below $0.08 If This Support FailsBusinessUBS maintains Rollins stock rating at Neutral on growth concernsBusinessUBS reiterates Danaher stock Buy rating on Q3 results and outlookBusinessStifel cuts argenx stock price target on mixed quarter resultsBusinessRBC Capital raises Meta stock price target to $800 on AI strengthBusinessUBS reiterates Thermo Fisher Scientific stock rating on solid quarterBusinessRBC cuts Aevex stock price target to $22 on contract concernsBusinessUBS reiterates Buy on Capital One stock, sees 20%+ ROTCE in 2027WorldTrade between China and Russia exceeds US$180 billion in first few months of 2026LocalA.I. and Its Dangers Are Embedded In the Midterm ElectionsTRENDING TICKERS: $NTCT $III $LSCC $NET $CALX $VG $GIL $FORR $RMNI $FROG $INV $DOCS $CC $RTX $ASTS $YSS $ERIC $LMT $CRWV $JKS $LINC $BBNX $LUMN $MRP $TBLA $QBTS $IQV $VEEV $RILY $ROKTechiPhone Duo buyers line up days early despite high chance of heartbreakMarketsVirginia state Sen. L. Louise Lucas, a Trump critic, charged in marijuana racketeering caseMarketsWedbush assumes coverage of five housing-related stocks after recent underperformanceLocalCompass sues former ERA president Alex Vidal over move to REMAXTechCoolfly’s solar-powered Aura Smart Bird Feeder is nearly 50 percent offTechApple Will Label Apps 'Made for iPhone Duo' in App StoreMarketsBrent crude rises to five-month high after more deadly attacks in Saudi ArabiaScienceThere should be black holes in our neighborhood. Can we find them?MarketsCBRE signals path to 15% core EPS growth in 2027 as it targets nearly $7B in infrastructure services revenueLocalCalifornia's Proposition 40: What voters need to know about billionaire wealth tax battleMarketsFireblocks disputes report of $2.5B Visa acquisition talksMarketsAmerican Express Q3 earnings watchlist: revenue, card spending, costsMarketsOmega Healthcare Investors raised to Buy-equivalent at Citizens after stock cools from 52-week highLocalIlhan Omar home raid, Haines attack: Inside rise in violence on officialsMarketsNvidia continues impressive path at GTC Berlin, BNP Paribas saysMarketsHBAR Risks a Retreat Below $0.08 If This Support FailsBusinessUBS maintains Rollins stock rating at Neutral on growth concernsBusinessUBS reiterates Danaher stock Buy rating on Q3 results and outlookBusinessStifel cuts argenx stock price target on mixed quarter resultsBusinessRBC Capital raises Meta stock price target to $800 on AI strengthBusinessUBS reiterates Thermo Fisher Scientific stock rating on solid quarterBusinessRBC cuts Aevex stock price target to $22 on contract concernsBusinessUBS reiterates Buy on Capital One stock, sees 20%+ ROTCE in 2027WorldTrade between China and Russia exceeds US$180 billion in first few months of 2026LocalA.I. and Its Dangers Are Embedded In the Midterm ElectionsTRENDING TICKERS: $NTCT $III $LSCC $NET $CALX $VG $GIL $FORR $RMNI $FROG $INV $DOCS $CC $RTX $ASTS $YSS $ERIC $LMT $CRWV $JKS $LINC $BBNX $LUMN $MRP $TBLA $QBTS $IQV $VEEV $RILY $ROK
Updated
AboutRSSSubmit a release
Markets

New bipartisan bill aims to speed up clinical trials for rare disease treatments

Source: CNBC ·
Emergency center entrance of a hospital in Saratoga Springs, New York
File photo P_R_F / Flickr · CC BY 2.0 · Source

The Quick Take

A new bipartisan bill aims to speed rare disease drug development by making clinical trials faster, cheaper and more accessible to patients.

Read the full story at CNBC

Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to CNBC.

More Markets

See all
North facade of the White House with its fountain and flowerbeds Markets

Virginia state Sen. L. Louise Lucas, a Trump critic, charged in marijuana racketeering case

The investigation into the Democrat predates the current Trump administration. But the timing of the indictment before the midterms has raised eyebrows.

CNBC · Trading floor of the New York Stock Exchange with banks of monitors Markets

Wedbush assumes coverage of five housing-related stocks after recent underperformance

Seeking Alpha · Aerial view of refinery storage tanks near Houston on the Gulf coast Markets

Brent crude rises to five-month high after more deadly attacks in Saudi Arabia

Seeking Alpha ·